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The relationship between obesity and hypertension is complex and poorly understood. A
developing body of information suggests that metabolic factors related to the obese state are
importantly involved. The pertinent observations include: (I) Diet influences sympathetic nervous
system activity. Fasting suppresses, while carbohydrate and fat feeding stimulate, sympathetic
activity. (2) Dietary-induced changes in sympathetic activity contribute to the changes in
metabolic rate that accompany changes in dietary intake. (3) Insulin-mediated glucose metabo-
lism in the hypothalamus provides a link between dietary intake and sympathetic nervous system
activity. And (4) hyperinsulinemia, a consequence of insulin resistance in the obese, is associated
with hypertension.
These observations have suggested the following hypothesis. Hyperinsulinemia results in
sympathetic stimulation which drives thermogenic mechanisms, thereby increasing metabolic
rate. The net result is a restoration of energy balance at the expense of hyperinsulinemia and
increased sympathetic activity. Hypertension is thus the unfortunate consequence of hyperinsu-
linemia, which increases renal sodium reabsorption, and sympathetic stimulation of the heart,
kidney, and vasculature. The data on which this hypothesis is constructed are reviewed and the
implications discussed.
Obesity and hypertension are curiously intertwined. The fact that obesity is
associated with increased blood pressure, and predicts the subsequent development of
hypertension in normotensives, is widely appreciated [1]; less well recognized is the
observation that lean hypertensive subjects are at increased risk ofbecoming obese [1].
The extent ofthe clinical problem is vast [2]: the incidence ofhypertension among the
obese approaches 50 percent in some age groups [1], and obesity accounts for a
substantial portion of overall hypertensive disease [1]. Despite the importance of the
problem, the nature of the association between blood pressure and obesity has
remained obscure.
Recent experimental observations have suggested that the linkage between obesity
and hypertension is rooted in the relationship between diet and the sympathetic
nervous system (SNS) [3,4,5]. Coupled with clinical and epidemiologic studies that
demonstrate an association between insulin levels and hypertension [6,7,8,9], these
observations have led to the development of an hypothesis that involves insulin-
mediated sympathetic stimulation in the pathogenesis ofobesity-related hypertension.
According to this hypothesis, the insulin resistance of obesity, and consequent
hyperinsulinemia, stimulates the SNS; sympathetic activity, in turn, increases thermo-
genesis, thereby restoring energy balance and limiting further weight gain. The
511
Abbreviations: BAT: brown adipose tissue NE: norepinephrine SNS: sympathetic nervous sys-
tem VMH: ventromedial hypothalamus
Supported in part by USPHS grants DK20378, HL37871, and RR01032
Address reprint requests to: Lewis Landsberg, M.D., Beth Israel Hospital, 333 Brookline Ave., Boston,
MA 02215
Copyright © 1989 by The Yale Journal of Biology and Medicine, Inc.
All rights ofreproduction in any form reserved.LEWIS LANDSBERG
hyperinsulinemia and sympathetic stimulation, however, via effects imposed on the
kidney, the heart, and the bloodvessels, result in hypertension [ 10]. The evidence upon
which this hypothesis is based is summarized herein.
DIET AND SYMPATHETIC NERVOUS SYSTEM ACTIVITY
Theapplication ofkinetic techniques to assess norepinephrine (NE) turnover rate in
sympathetically innervated tissues of laboratory rodents has permitted a detailed
evaluation of the influence ofdietary intake on SNS activity in these species [1]. The
following observations about diet and sympathetic activity have been made: (i) Fasting
suppresses sympathetic activity [12]. (ii) Overfeeding stimulates the SNS [13].(iii)
Dietary carbohydrate and dietary fat stimulate sympathetic activity even when total
caloric intake is not increased [14,15,16]. (iv) Low-protein diets stimulate the SNS
[17], while protein is without effect [18]. (v) Dietary changes in sympathetic activity
depend upon absorption of the specific nutrient. Fat malabsorption induced by
cholestyramine antagonizes the stimulatory effect of fat but not of sucrose [15]; the
stimulatory effect of sucrose, on the other hand, is antagonized by the disaccharidase
inhibitor, acarbose [16].
Although originally described in rodents, theapplication of less sensitive techniques
in human subjects demonstrates that dietary changes in sympathetic activity occur in
humans as well [19,20].
DIETARY THERMOGENESIS
Dietary thermogenesis refers to alterations in metabolic rate that accompany
changes in dietary intake. Twocomponents have been identified: an increase in oxygen
consumption in the postprandial state over and above that accounted for by the
metabolic disposition of the nutrients [21,22] and an effect of antecedent diet on the
resting metabolic rate [23,24]. It is generally acknowledged that dietary changes in
thermogenesis are mediated, at least in part, by dietary changes in sympathetic
activity. The linkage between dietary thermogenesis and the sympathetic nervous
system depends, in part, on observations demonstrating that diet influences sympa-
thetic outflow to brown adipose tissue in the rodent [13]. Brown adipose tissue (BAT)
is the thermogenic effector organ in the rat [25]; the SNS is the major physiologic
regulator ofheat production in this organ [26]. Sympatheticstimulation of this organ
enhances the synthesis ofuncoupling protein, a unique BAT polypeptide that permits
protons to enter the inner mitochondrial matrix without the concomitant synthesis of
ATP, thereby driving the respiratory chain and uncoupling oxidative phosphorylation
[27]. The observation that diet exerts an important influence on sympathetic outflow
to BAT [13] as well as heart provides a link between dietary intake and oxygen
consumption or thermogenesis. The fact that diet is without effect on sympathetic
outflow to skeletal muscle, conversely, is evidence against muscle as an important site
ofdietary thermogenesis in the rodent [28]. Although a decisive role for BAT in adult
humans is still controversial [29,30], studies utilizing beta adrenergic antagonists are
consistent with a role for the SNS in the regulation of dietary thermogenesis in man
[21,22,24].
Suppression of sympathetic activity with fasting would serve the useful role of
diminishing energy expenditure in the face of diminished caloric intake, thereby
prolonging survival during famine. Thecapacity to enhance thermogenesis in the face
of a subsistence diet low in protein would, on the other hand, permit an organism to
maintain adequate supplies of nitrogen for growth and development by overeating a
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FIG. 1. Insulin-mediated glucose metabolism in the regulation of sympathetic outflow.
According to this model, insulin-mediated glucose metabolism within insulin-glucose sensitive
neurons related anatomically to the ventromedial hypothalamus (VMH) regulates discharge in
sympathetic brainstem centers via an inhibitory pathway. The data on which this model is based
are summarized in the text. Diminished circulating levels of insulin and glucose, such as occur
during fasting or caloric restriction, diminish insulin-mediated glucose uptake and metabolism in
hypothalamic regulatory neurons sensitive to glucose and insulin. This decrease in intracellular
glucose metabolism enhances an inhibitory pathway to the brainstem, thereby diminishing
sympathetic outflow. Conversely, during carbohydrate intake, or in the presence of insulin
resistance, elevated levels ofglucose and insulin stimulate glucose uptake and metabolism in these
same neurons. Increased intracellular glucose metabolism inhibits the inhibitory pathway to the
brainstem, resulting in disinhibition of tonically active lower neurons and an increase in central
sympathetic outflow (from [32] with permission).
diet low in protein while avoiding obesity by dissipating the excess calories. Whatever
the evolutionary origins of dietary thermogenesis, however, it is clear that this
mechanism would allow an organism to maintain energy balance over a variable range
ofdietary intakes. A mismatch ofintake over expenditure ofa few percent would, over
time, result in the accumulation ofsignificant amounts offat [311. Dietary thermogen-
esis, therefore, to the extent that it is expressed in a given individual, provides a buffer
against the development ofobesity.
ROLE OF INSULIN
The mediation ofdietary changes in sympathetic activity is a subject ofconsiderable
interest. Since sympathetic outflow depends upon integrated changes within the
central nervous system, mechanisms must exist that couple sympathetic outflow with
changes in dietary intake. Evidence accumulated over the last decade indicates that
insulin-mediated glucose metabolism within critical central neurons sensitive to insulin
and glucose is critically involved in this linkage of diet and SNS [32] (Fig. 1). The
following observations bear importantly on this relationship: (i) Hypoglycemia sup-
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presses sympathetic activity despite concomitant adrenal medullary stimulation
[33,34]. (ii) 2-Deoxyglucose administration suppresses sympathetic activity (despite
adrenal medullary stimulation) in the face ofincreased circulating glucose levels [35].
(iii) Insulin administration, to rats and humans, along with provision of sufficient
glucose to prevent the development of hypoglycemia, stimulates the SNS [36,37]. (iv)
The induction of experimental diabetes in rats with streptozotocin, conversely,
diminishes sympathetic activity despite the elevated glucose levels [38]. (v) Gold-
thioglucose treatment in mice, which destroys insulin-glucose sensitive neurons related
to the ventromedial portion of the hypothalamus, blocks dietary changes in sympa-
thetic activity. Animals treated with gold-thioglucose fail to suppress sympathetic
activity with fasting [39], implying that fasting is normally associated with stimulation
of an inhibitory pathway from the hypothalamus to tonically active regulatory
sympathetic centers in the brainstem (Fig. 1).
The fact that fasting and 2-deoxyglucose are not additive in their suppressive effect
on sympathetic activity suggests that the fasting effect is induced by diminished
glucose metabolism in the central nervous system [35]. Fasting, therefore, appears to
suppress sympathetic activity by decreasing insulin-mediated glucose metabolism
(within these critical hypothalamic neurons) which in turn stimulates an inhibitory
pathway to the brainstem. Enhanced insulin-mediated glucose metabolism in these
neurons, conversely, suppresses the inhibitory pathway, resulting in disinhibition of
tonically active lower neurons and an increase in sympathetic outflow. The develop-
ment of insulin resistance in response to fat feeding, associated as it is with elevated
levels of insulin and glucose, would be expected to stimulate sympathetic activity in a
manner analogous to that shown for carbohydrate intake in Fig. 1.
Insulin, therefore, serves as an important signal that couples dietary intake and
sympathetic outflow.
INSULIN AND BLOOD PRESSURE IN THE OBESE
Clues to the involvement of insulin in the pathogenesis of obesity-related hyperten-
sion came initially from two sources. Epidemiologic studies oflarge population groups
demonstrated that the cardiovascular and metabolic complications of obesity, includ-
ing hypertension, were associated with a pattern of body fat distribution that favored
the upper body segments [40,41,42]. Clinical studies of smaller numbers of obese
subjects demonstrated that hyperinsulinemia and insulin resistance were more marked
in obese subjects with this same upper body fat distribution [43,44,45]. A direct link
between insulin and blood pressure was also demonstrated in epidemiological [8] and
clinical studies of obese subjects [6,7]. Both clinical and epidemiologic studies have,
moreover, demonstrated that hyperinsulinemia and insulin resistance are noted in
non-obese hypertensives as well [8,9].
The relationship between hyperinsulinemia and blood pressure remains obscure. A
plausible hypothesis relating insulin to hypertension, however, can be constructed from
the direct effects of insulin on renal sodium reabsorption and the effects of insulin on
the SNS as summarized in Fig. 2. According to this formulation, the hypertension
associated with hyperinsulinemia results from the antinatriuretic effects of insulin
[46,47] and the SNS [48,49,50] in conjunction with sympathetic stimulation of the
heart and vasculature [51]. Antinatriuretic effects induce hypertension by shifting the
pressure-natriuresis relationship so that higher renal perfusion pressures are required
to maintain extracellular fluid volume [52,53]. Insulin and sympathetic stimulation in
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pathogenesis of obesity-related
INSULIN-MEDIATED SYMPATHETIC STIMULATION IN THE OBESE
A larger question is the physiological role subserved by the development of insulin
resistance in the obese. A potential role for insulin resistance and hyperinsulinemia in
the metabolic economy of the obese is suggested in Fig. 2. Insulin resistance may be
viewed as a mechanism recruited in the obese to restore energy balance and limit
further weight gain. Insulin resistance at the level of the adipocyte would antagonize
the deposition of free fatty acids in triglyceride stores in adipose tissue. The
hyperinsulinemia that develops as a consequence of insulin resistance might, further-
more, stimulate sympathetically mediated thermogenesis, thereby increasing energy
production, restoring energy balance, and limiting further weight gain. According to
the hypothesis presented in Fig. 2, thermogenesis is enhanced at the expense of
hyperinsulinemia and SNS stimulation in the obese. Such a mechanism would come
into play in the setting of either excessive dietary intake or diminished thermogenic
capability.
In support of the above hypothesis, it has been demonstrated that insulin infusions
increase plasma NE level in lean [36] and obese [54] subjects, along with cardiovascu-
lar and thermogenic manifestations of sympathetic stimulation. The obese, therefore,
are not resistant to the effect of insulin on the SNS. The linchpin of the hypothesis,
nonetheless, is the level of sympathetic activity in obese hypertensives. This level
remains the subject of ongoing investigation but preliminary epidemiologic [55] and
clinical studies utilizing somatostatin infusions to suppress insulin release [D. Elahi
\(+)
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and L. Landsberg] are consistent with increased sympathetic stimulation in the
obese.
INSULIN-MEDIATED SNS STIMULATION
IN NON-OBESE HYPERTENSIVES
Hypertension in the obese, therefore, may be the unwelcome consequence of
mechanisms recruited primarily to restore energy balance. Since the morbid complica-
tions of hypertension are not usually expressed during the reproductive years, genetic
pressure against insulin-mediated sympathetic stimulation would be unlikely. Inspec-
tion of Fig. 2, moreover, suggests that similar mechanisms may be involved in the
pathogenesis of hypertension in the non-obese as well. In the presence of effective
thermogenic mechanisms, increased dietary intake with consequent hyperinsulinemia
and sympathetic stimulation might compensate effectively for the increase in caloric
consumption. The compensatory mechanisms, however, involving insulin and the
sympathetic nervous system might contribute to the development of hypertension.
Since thermogenic capability is known to diminish with advancing age, the mecha-
nisms shown in Fig. 2 might explain the puzzling observation that hypertension
predisposes to the development of obesity [1]. As the capacity for thermogenesis
diminishes, the mechanism outlined in Fig. 2 would compensate less effectively for
increased dietary intake. Under these circumstances, the consequences of continued
excessive dietary intake would be the development ofobesity along with hypertension.
THERAPEUTIC IMPLICATIONS
This model has clear therapeutic implications. Non-pharmacologic interventions
that increase insulin sensitivity and decrease insulin secretion would be expected to
reduce SNS activity and lower blood pressure. Decreased caloric intake, weight loss,
exercise, and high-fiber diets have all been proposed as effective forms oftreatment for
obesity-related hypertension [56,57,58,59]. Each of these modalities increases insulin
sensitivity and decreases insulin secretion and, where studied, have been shown to
diminish SNS activity.
Caloric restriction exerts a hypotensive effect soon after the initiation of a
low-energy diet [56], before appreciable loss ofweight. The hypotensive effect appears
to reflect alterations in renal sodium excretion (the "natriuresis of fasting") [60] and
suppression of the SNS [61,62]. Weight loss has also been demonstrated to lower
blood pressure in obese hypertensives [63], although this effect may be difficult to
distinguish from caloric restriction. Diminished insulin resistance and decreased SNS
activity are likely to be involved in the hypotensive response [64]. Interestingly,
relatively small amounts of weight loss may be efficacious in lowering blood pressure
[65]. Exercise lowers blood pressure with a greater effect in hypertensives than in
normotensives, even in the absence of weight loss [57,59]. Training is known to
decrease sympathetic activity and increase insulin sensitivity as well, consistent with
involvement in the hypotensive response to exercise.
The beneficial effects of each of these interventions is consistent with the model
depicted in Fig. 2 and suggests that other treatment strategies directed at insulin
resistance and the SNS may be effective as well.
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